Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies. Issue 2 (27th December 2018)

• Record Type: Journal Article
• Authors: Leipold, Douglas; Prabhu, Saileta
• Is Part Of: Clinical and translational science. Volume 12:Issue 2(2019)
• Page Start: 130
• Page End: 139
• Publication Date: 2018-12-27
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.12597
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract : The design and development of therapeutic monoclonal antibodies (mAbs) through optimizing their pharmacokinetic (PK) and pharmacodynamic (PD) properties is crucial to improve efficacy while minimizing adverse events. Many of these properties are interdependent, which highlights the inherent challenges in therapeutic antibody design, where improving one antibody property can sometimes lead to changes in others. Here, we discuss optimization approaches for PK/PD properties of therapeutic mAbs.